{"schema_version":"secwatch.filing_event.v1","accession":"0001299130-24-000005","form_type":"8-K","ticker":"PACB","cik":"0001299130","company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.711973+00:00","generated_at":"2026-06-07T02:03:26.286195+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"PacBio reports record preliminary Q4 revenue $58.4M, up 113% YoY; Revio installed base 173","bullets":["Preliminary full year 2023 revenue $200.5M, up 56% YoY; Q4 revenue $58.4M (+113% YoY).","Shipped 44 Revio systems in Q4, total installed base 173; annualized pull-through ~$385K per system.","Preliminary Q4 consumables revenue $18.9M (67% from Revio); instrument revenue $35.1M.","Cash, equivalents, and investments $631M as of Dec 31, 2023.","Reaffirms 40-50% annual revenue growth target through 2026, aiming for >$500M in 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001299130-24-000005","json":"https://secwatch.observer/filing/0001299130-24-000005.json","markdown":"https://secwatch.observer/filing/0001299130-24-000005.md","text":"https://secwatch.observer/filing/0001299130-24-000005.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1299130/000129913024000005/0001299130-24-000005-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1299130/000129913024000005/pacb-20240108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:03:26.286195+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"053629b66aa00d25d67d9b95a87e2c1973d4080a","claim":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reported the full year ended December 31, 2023 results: revenue $200.5 million. Guidance reaffirmed.","evidence_excerpt":"announced preliminary unaudited revenue for the fourth quarter 2023 and full year 2023 of $58.4 million and $200.5 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1299130/000129913024000005/0001299130-24-000005-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended December 31, 2023"},{"label":"Revenue","value":"$200.5 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"154997ac203b2903e329ca52093dd11cfdbd8375","claim":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reported the fourth quarter ended December 31, 2023 results: revenue $58.4 million. Guidance reaffirmed.","evidence_excerpt":"PacBio reported preliminary, unaudited revenue of approximately $58.4 million for its fourth quarter ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1299130/000129913024000005/0001299130-24-000005-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2023"},{"label":"Revenue","value":"$58.4 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}